China ranks second in the world in the number of new drugs under development.
Recently, it was learned from the China Pharmaceutical Industry Development Conference that China’s pharmaceutical industry has accelerated its development, its innovation capabilities have been significantly enhanced, and the number of new drugs under development has jumped to second in the world. Since last year, 37 innovative drugs and 51 innovative medical devices have been approved for marketing, and cutting-edge fields such as new antibodies and cell and gene therapy drugs have ranked among the world’s top.
At the same time, the scale of the industry continues to grow. Last year, the growth rate of the added value of the national pharmaceutical industry reached 10.5%, accounting for 3.7% of the total industrial proportion, and the market size of innovative drugs exceeded 100 billion yuan. International cooperation continues to deepen. Last year, Chinese pharmaceutical companies’ total transaction scale of foreign technology licensing exceeded US$34 billion. Several high-quality Chinese patent medicines have gone global and have obtained 503 registration certificates in 47 countries and regions.
In the future, China will continue to promote transforming and upgrading the pharmaceutical industry. Adhere to high-end, intelligent, and green development; improve the quality management system; continuously improve the quality level of the entire industry of drugs and medical devices; and cultivate a group of world-class pharmaceutical companies. In addition, further expand the open cooperation of the pharmaceutical industry to attract the global pharmaceutical industry technology, capital, talents and other innovative elements to gather. Actively explore the international market and integrate into the global pharmaceutical innovation network and industrial system at a higher level.